uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Clonal B-cell lymphocytosis of marginal zone origin
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology. Uppsala University, Science for Life Laboratory, SciLifeLab. Inst Appl Biosci, CERTH, Thessaloniki 57001, Greece..
Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology. Uppsala University, Science for Life Laboratory, SciLifeLab. Inst Appl Biosci, CERTH, Thessaloniki 57001, Greece..
2017 (English)In: Baillière's Best Practice & Research: Clinical Haematology, ISSN 1521-6926, E-ISSN 1532-1924, Vol. 30, no 1-2, p. 77-83Article in journal (Refereed) Published
Abstract [en]

Monoclonal B cell Lymphocytosis (MBL) is the term used to characterize individuals presenting with lymphocytosis in the absence of lymphadenopathy, organomegaly or any other features suggestive of an active disease. Based on the immunophenotypic findings, MBL cases are sub-categorized into chronic lymphocytic leukemia (CLL)-like, atypical CLL and non-CLL MBL. The latter corresponds to cases with immunophenotypic features suggestive of post germinal center derivation and still represents a diagnostic conundrum. Recent studies are starting to shed light on the true biological nature and clinical significance of this entity and have led to the introduction of the novel term clonal B lymphocytosis of marginal-zone origin (CBL-MZ); as well as the acknowledgement of CBL-MZ in the latest (2016) update of the WHO classification for lymphoid malignancies. Here we provide an overview of relevant research concerning non-CLL MBL and discuss clinicobiological implications and considerations.

Place, publisher, year, edition, pages
ELSEVIER SCI LTD , 2017. Vol. 30, no 1-2, p. 77-83
Keywords [en]
CD5(-) lymphocytosis, Monoclonal B cell lymphocytosis, Marginal zone
National Category
Hematology
Identifiers
URN: urn:nbn:se:uu:diva-320832DOI: 10.1016/j.beha.2016.08.028ISI: 000397692700010PubMedID: 28288720OAI: oai:DiVA.org:uu-320832DiVA, id: diva2:1091459
Available from: 2017-04-26 Created: 2017-04-26 Last updated: 2017-04-26Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Xochelli, AlikiStamatopoulos, Kostas

Search in DiVA

By author/editor
Xochelli, AlikiStamatopoulos, Kostas
By organisation
Experimental and Clinical OncologyScience for Life Laboratory, SciLifeLab
In the same journal
Baillière's Best Practice & Research: Clinical Haematology
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 254 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf